Terns Pharmaceuticals, Inc. ( TERN )

Derivative

Stock Option (Right to Buy)

64,000^{footnote F1}

-^{footnote F2}

May 5, 2026

Derivative

Stock Option (Right to Buy)

45,000^{footnote F1}

-^{footnote F2}

May 5, 2026

Derivative

Stock Option (Right to Buy)

10,657^{footnote F1}

-^{footnote F2}

May 5, 2026

Derivative

Stock Option (Right to Buy)

4,676^{footnote F1}

-^{footnote F2}

May 5, 2026

Derivative

Stock Option (Right to Buy)

32,000^{footnote F1}

-^{footnote F2}

May 5, 2026

Derivative

Stock Option (Right to Buy)

32,000^{footnote F1}

-^{footnote F2}

May 5, 2026

Derivative

Stock Option (Right to Buy)

1,697^{footnote F1}

-^{footnote F2}

Footnote F1 (shares): Pursuant to the Merger Agreement, at the Effective Time (as defined in the Merger Agreement), each option to purchase the Issuer's Shares that was outstanding and unexercised immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was… Full note on SEC EDGAR
Footnote F2 (price): On March 24, 2026, Terns Pharmaceuticals, Inc. (the "Issuer") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Merck Sharp & Dohme LLC ("Merck") and Thailand Merger Sub, Inc. (the "Purchaser"), a wholly owned subsidiary of Merck. Pursuant to the Merger… Full note on SEC EDGAR

May 5, 2026

Derivative

Stock Option (Right to Buy)

45,000^{footnote F1}

-^{footnote F2}

May 5, 2026

Derivative

Stock Option (Right to Buy)

10,657^{footnote F1}

-^{footnote F2}

May 5, 2026

Derivative

Stock Option (Right to Buy)

32,000^{footnote F1}

-^{footnote F2}

May 5, 2026

Derivative

Stock Option (Right to Buy)

32,000^{footnote F1}

-^{footnote F2}

May 5, 2026

Derivative

Stock Option (Right to Buy)

3,955^{footnote F1}

-^{footnote F2}

May 5, 2026

Derivative

Stock Option (Right to Buy)

22,000^{footnote F1}

-^{footnote F2}

May 5, 2026

Derivative

Stock Option (Right to Buy)

1,697^{footnote F1}

-^{footnote F2}

Footnote F1 (shares): Pursuant to the Merger Agreement, at the Effective Time (as defined in the Merger Agreement), each option to purchase the Issuer's Shares that was outstanding and unexercised immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was… Full note on SEC EDGAR
Footnote F2 (price): On March 24, 2026, Terns Pharmaceuticals, Inc. (the "Issuer") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Merck Sharp & Dohme LLC ("Merck") and Thailand Merger Sub, Inc. (the "Purchaser"), a wholly owned subsidiary of Merck. Pursuant to the Merger… Full note on SEC EDGAR

May 5, 2026

Derivative

Stock Option (Right to Buy)

32,000^{footnote F1}

-^{footnote F2}

May 5, 2026

Derivative

Stock Option (Right to Buy)

32,000^{footnote F1}

-^{footnote F2}

May 5, 2026

Derivative

Stock Option (Right to Buy)

32,000^{footnote F1}

-^{footnote F2}

May 5, 2026

Derivative

Stock Option (Right to Buy)

45,000^{footnote F1}

-^{footnote F2}

May 5, 2026

Derivative

Stock Option (Right to Buy)

10,657^{footnote F1}

-^{footnote F2}

May 5, 2026

Derivative

Stock Option (Right to Buy)

4,676^{footnote F1}

-^{footnote F2}

May 5, 2026

Derivative

Stock Option (Right to Buy)

28,475^{footnote F1}

-^{footnote F2}

May 5, 2026

Derivative

Stock Option (Right to Buy)

22,000^{footnote F1}

-^{footnote F2}

May 5, 2026

Derivative

Stock Option (Right to Buy)

1,697^{footnote F1}

-^{footnote F2}

Footnote F1 (shares): Pursuant to the Merger Agreement, at the Effective Time (as defined in the Merger Agreement), each option to purchase the Issuer's Shares that was outstanding and unexercised immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was… Full note on SEC EDGAR
Footnote F2 (price): On March 24, 2026, Terns Pharmaceuticals, Inc. (the "Issuer") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Merck Sharp & Dohme LLC ("Merck") and Thailand Merger Sub, Inc. (the "Purchaser"), a wholly owned subsidiary of Merck. Pursuant to the Merger… Full note on SEC EDGAR

May 5, 2026

Derivative

Stock Option (Right to Buy)

32,000^{footnote F1}

-^{footnote F2}

May 5, 2026

Derivative

Stock Option (Right to Buy)

32,000^{footnote F1}

-^{footnote F2}

May 5, 2026

Derivative

Stock Option (Right to Buy)

32,000^{footnote F1}

-^{footnote F2}

May 5, 2026

Derivative

Stock Option (Right to Buy)

45,000^{footnote F1}

-^{footnote F2}

May 5, 2026

Derivative

Stock Option (Right to Buy)

18,650^{footnote F1}

-^{footnote F2}

May 5, 2026

Derivative

Stock Option (Right to Buy)

8,183^{footnote F1}

-^{footnote F2}

May 5, 2026

Derivative

Stock Option (Right to Buy)

28,475^{footnote F1}

-^{footnote F2}

May 5, 2026

Derivative

Stock Option (Right to Buy)

22,000^{footnote F1}

-^{footnote F2}

May 5, 2026